Not available
Quote | VBI Vaccines Inc. (NASDAQ:VBIV)
Last: | $0.711 |
---|---|
Change Percent: | -1.16% |
Open: | $0.7 |
Close: | $0.711 |
High: | $0.7799 |
Low: | $0.6849 |
Volume: | 383,429 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | VBI Vaccines Inc. (NASDAQ:VBIV)
Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response (PR) and two stable disease (SD) observations have occurred as of May 15, 2024 The partial response, which demonstrated a 67% reduction in tumor size vs. baseline, wa...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s ca...
Message Board Posts | VBI Vaccines Inc. (NASDAQ:VBIV)
Subject | By | Source | When |
---|---|---|---|
$VBIV no 1 in the Gaucho session | Monksdream | investorshub | 07/05/2023 8:23:32 PM |
Zoom Zoom WOOHOOOOOO WOOHOOOOOO $VBIV | weedtrader420 | investorshub | 07/05/2023 8:12:19 PM |
$VBIV: BBOOoooommmmmmmmm.............. moved now to $3.50 | makinezmoney | investorshub | 07/05/2023 8:02:51 PM |
$VBIV where is the squeeze? | cheynew | investorshub | 07/04/2023 4:43:59 PM |
$VBIV The gaining | cheynew | investorshub | 07/04/2023 11:59:28 AM |
News, Short Squeeze, Breakout and More Instantly...
Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response (PR) and two stable disease (SD) observations have occurred as of May 15, 2024 The partial response, which demonstrated a 67% reduction in tumor size vs. baseline, wa...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s ca...
PreHevbrio ® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 105% year-over-year in the first quarter of 2024 compared to the first quarter of 2023 Initial encouraging tumor response data from randomized Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) anno...